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OBJECTIVE—Recent data from the Diabetes Control and Com-
plications Trial (DCCT) indicated that A1C variability is associ-
ated with the risk of diabetes microvascular complications.
However, these results might have been inﬂuenced by the
interventional study design. Therefore, we investigated the lon-
gitudinal associations between A1C variability and diabetes
complications in patients with type 1 diabetes in the observa-
tional Finnish Diabetic Nephropathy (FinnDiane) Study.
RESEARCH DESIGN AND METHODS—A total of 2,107 pa-
tients in the FinnDiane Study had complete data on renal status
and serial measurements of A1C from baseline to follow-up
(median 5.7 years), and 1,845 patients had similar data on
cardiovascular disease (CVD) events. Intrapersonal SD of serially
measured A1C was considered a measure of variability.
RESULTS—During follow-up, 10.2% progressed to a higher
albuminuria level or to end-stage renal disease, whereas 8.6% had
a CVD event. The SD of serial A1C was 1.01 versus 0.75 (P 
0.001) for renal status and 0.87 versus 0.79 (P  0.023) for CVD
in progressors versus nonprogressors, respectively. In a Cox
regression model, SD of serial A1C was independently associated
with progression of renal disease (hazard ratio 1.92 [95% CI
1.49–2.47]) and of a CVD event (1.98 [1.39–2.82]) even when
adjusting for mean A1C and traditional risk factors. Interestingly
for CVD, mean serial A1C itself was not predictive even though
SD of A1C was.
CONCLUSIONS—In patients with type 1 diabetes, A1C variabil-
ity was not only predictive of incident microalbuminuria and
progression of renal disease but also of incident CVD events.
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A
substantial proportion of patients with type 1
diabetes develops diabetes complications, such
as microvascular complications (nephropathy,
retinopathy, and neuropathy) and cardiovascu-
lar disease (CVD). Among the risk factors that have been
identiﬁed for the microvascular complications, glycemic
control is perhaps one of the most important. There is
compelling evidence that the level of long-term glycemia,
clinically determined by the A1C test, inﬂuences the risk of
microvascular disease in patients with type 1 diabetes. The
landmark study DCCT (Diabetes Control and Complica-
tions Trial) showed that a mean reduction in A1C by 2%
units reduced the incidence of nephropathy by 54% and
retinopathy by 76% (1). However, regarding CVD, the
results were ambiguous because of the low incidence of
CVD in this young cohort. Nevertheless, in the extended
follow-up, the EDIC (Epidemiology of Diabetes Interven-
tions and Complications) study, the risk of coronary heart
disease was reduced by 42% in patients originally allocated
to the intensively treated group (2).
In addition to the level of long-term glycemia, it has been
debated whether glycemic variability confers additional
risk of diabetes complications. Patients with identical A1C
values may still show large variation in their glycemic
excursions. In theory, a highly variable glucose proﬁle
could confer a greater risk of diabetes complications
through increased oxidative stress (3). The clinical evi-
dence is so far scarce, which may be because of a lack of
a standardized method to measure glycemic variability in a
large number of patients. In the DCCT, variation in seven-
point laboratory-measured glucose proﬁles did not predict
diabetes complications (4). However, a recent analysis of
the DCCT data indicated that variation in the long-term
glycemia, deﬁned as intrapersonal SDs of quarterly mea-
sured A1C, added to the predictive value of A1C level
alone for both nephropathy and retinopathy (5). This is a
potentially important clinical ﬁnding, but since the DCCT
was an intervention focusing on the A1C, the results might
not reﬂect the situation in a normal clinical setting.
Therefore, we analyzed the effect of both the mean A1C
and the variability of A1C on the prediction of diabetes
complications in the observational, longitudinal Finnish
Diabetic Nephropathy (FinnDiane) Study.
RESEARCH DESIGN AND METHODS
The FinnDiane Study is an ongoing, nationwide, prospective multicenter study
seeking for clinical, genetic, biochemical, and environmental risk factors for
diabetes complications, with emphasis on diabetic nephropathy. Participating
study centers comprise diabetes and renal outpatient clinics at all ﬁve
university central hospitals, all 16 central hospitals, the majority (N  27) of
all regional hospitals, and 31 major primary health care centers in Finland.
Patients with type 1 diabetes (ICD-10 code E10) were recruited at routine
outpatient visits. Based on medical records, the attending physician com-
pleted a standardized check-list regarding diabetes complications and medi-
cation. Patients answered a self-report questionnaire regarding lifestyle
factors and socioeconomic status. Total leisure-time physical activity was
assessed by a separate questionnaire as previously described (6), and low
physical activity was deﬁned as 10 MET*h/week. Physical activity data were
available for 775 eligible patients, and we also performed a subanalysis
including only patients (N  534) with physical activity data and normal
urinary albumin excretion rate (UAER) because of a possible confounding
effect of diabetes complications as we have shown decreased physical activity
in patients with diabetes complications (7). Serum lipids were determined by
From the
1Folkha ¨lsan Institute of Genetics, Folkha ¨lsan Research Center,
Helsinki, Finland; and the
2Department of Medicine, Division of Nephrol-
ogy, Helsinki University Central Hospital, Helsinki, Finland.
Corresponding author: Per-Henrik Groop, per-henrik.groop@helsinki.ﬁ.
Received 8 May 2009 and accepted 14 July 2009. Published ahead of print
at http://diabetes.diabetesjournals.org on 3 August 2009. DOI: 10.2337/
db09-0693.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2649automated enzymatic methods using a Cobas Mira analyzer (Hoffman-
LaRoche, Basel, Switzerland). As an estimate of insulin sensitivity, the formula
for estimated glucose disposal rate (eGDR) was used as previously described
(8). Blood pressure was measured in the sitting position twice, and the mean
value was used.
The study was initiated in November 1997 and follow-up data have been
collected since 2004 either by reexamination of the patients or review of the
medical ﬁles. Written informed consent was obtained from each patient, and
the study protocol was conducted in accordance with the Declaration of
Helsinki. In the present analyses, type 1 diabetes was restricted to age at onset
of diabetes below 35 years and insulin treatment initiated within 1 year of
diagnosis. In January 2009, the FinnDiane database comprised 2,107 patients
with type 1 diabetes, serial data on A1C, and known renal status both at
baseline and at follow-up, and these were included in the analyses.
Serial A1C measurements. A1C was measured at the local study centers
with standardized assays (normal range 4.0–6.0%). The nationwide validity of
A1C measurements in Finland has previously been studied, showing a high
correlation with the DCCT reference method (9). Laboratory records of A1C
measurements from baseline to follow-up were obtained. During a median
follow-up of 5.7 years, the median number of A1C measurements per patient
was 13 (interquartile range 7–20), that is 2.3 measurements per patient and
year. For each patient, intrapersonal mean and SDs of all recorded A1C
measurements were calculated, and the SD was considered a measure of A1C
variability. As a normalized measure of variability, the coefﬁcient of variation
for A1C was calculated as the ratio of intrapersonal SD and mean to correct
for larger SD because of higher absolute values of A1C.
Diabetes complications. Renal status was deﬁned based on UAER in at least
two of three consecutive timed (either 24 h or overnight) urine collections.
Microalbuminuria was deﬁned as UAER 30 and 300 mg/24 h or 20 and
200 g/min, respectively. Macroalbuminuria was deﬁned as UAER 300
mg/24 h or 200 g/min, respectively. End-stage renal disease (ESRD) was
deﬁned as hemodialysis, peritoneal dialysis, or renal transplantation. Diabetic
nephropathy was deﬁned as macroalbuminuria and/or ESRD. Renal status
was prospectively assessed by review of all recorded values of UAER and of
medical records. Progression of renal disease was deﬁned as a shift to a higher
albuminuria level in any two (of three) consecutive urine collections or to
ESRD. CVD was deﬁned based on medical records both at baseline and at
follow-up as any of the following hard events: myocardial infarction, coronary
artery procedure (by-pass surgery or angioplasty), stroke (ischemic or hem-
orrhagic), limb amputation because of ischemia, or a peripheral artery
procedure. Of the 2,107 patients with complete data on renal status and serial
A1C measurements, 1,845 patients (87.6%) had follow-up data on CVD events.
Patients with and without CVD data did not differ according to sex, age,
duration of diabetes, CVD, or nephropathy status at baseline.
Statistical analyses. Continuous variables are expressed as means  SD if
normally distributed, otherwise as median (interquartile range). Categorical
variables are reported as percentages. Differences between groups were
analyzed by Student t test (two groups) or ANOVA (over two groups) for
normally distributed continuous variables, otherwise the Mann-Whitney or
Kruskal-Wallis was used, respectively. The 
2 test was used for categorical
variables. When P values were adjusted for age, ANCOVA was used for
continuous variables and logistic regression for categorical variables. In
cross-sectional data, logistic regression was used as multivariate analysis.
Longitudinal data were analyzed with Kaplan-Meier survival curves with
log-rank tests and Cox proportional hazard survival regression with results as
hazard ratio (HR) and 95% CI. SPSS version 15.0 (SPSS, Chicago, IL) was used
for statistical calculations, and survival cures were drawn by GraphPad Prism
5 (GraphPad Software, La Jolla, CA).
RESULTS
Patient characteristics. Of the eligible 2,107 patients,
53.2% of patients were men and the mean age was 36.4 
11.8 years, duration of diabetes 22.0  11.9 years, BMI
25.0  3.5 kg/m
2, and A1C 8.5  1.5% at baseline. Alto-
gether 1,381 patients had normal UAER, 316 microalbu-
minuria, 302 macroalbuminuria, and 108 ESRD. During a
median follow-up of 5.7 years, 214 patients (10.2%) pro-
gressed to a higher level of albuminuria or to ESRD and
158 suffered a CVD event (of 1,845 with data on CVD;
8.6%). In Table 1, baseline characteristics according to
progression in renal status and occurrence of a CVD event
are given. For A1C there was a considerably larger differ-
ence for progression in renal status (1.0% unit) than for a
CVD event (0.2% unit) (Table 1).
Serial A1C measurements. Intrapersonal mean of seri-
ally measured A1C was 8.5% and SD 0.78. There was a
clear correlation between baseline single-measured A1C
and the mean of serial A1C (Pearson r  0.72, P  0.001).
According to baseline renal status, patients with normo-,
micro-, or macroalbuminuria and ESRD had an SD of A1C
during follow-up as follows: 0.75, 0.82, 0.89, and 0.79
(overall P  0.0001), respectively. Patients that progressed
regarding their renal status had a median of 15 A1C
measurements, whereas nonprogressors had a median of
13 measurements (P  0.012), but for CVD events there
was no such corresponding difference (P  0.907). In
Table 2, mean and SD of serial A1C is given according to
progression in renal and CVD status. The level of mean
serial A1C was higher in patients that progressed to a
higher albuminuria level (but not to ESRD), but no differ-
ence was seen in mean A1C between patients with and
without a CVD event (Table 2). The variability (SD) of
A1C, on the other hand, was greater in all subgroups of
patients that progressed in renal status and in patients
with a CVD event during follow-up (Table 2). In addition,
the ﬁnding for coefﬁcient of variation was similar to that of
SD, indicating that the differences in SD were not solely
because of differences in absolute A1C level between
progressors and nonprogressors (Table 2).
To address the possibility of bias by the number of A1C
measurements, we compared SD of progression versus
nonprogression in renal status in patients with different
numbers of measurements; 10 measurements: 0.98 ver-
TABLE 1
Baseline characteristics according to progression in renal status (deﬁned as any increase in albuminuria level or progression to
ESRD) and occurrence of a hard CVD event (coronary event, stroke, peripheral vascular event) during follow-up
Progression in renal status CVD event
Nonprogressors Progressors No event Event
n 1,893 214 1,687 158
Sex (% male) 52.0 64.8* 52.0 62.4#
Age (years) 36.5  11.9 36.1  11.1 35.2  11.4 47.9  9.0#
Duration of diabetes (years) 21.8  11.9 23.1  11.1 20.8  11.4 34.6  8.6#
A1C (%) 8.4  1.4 9.4  1.7* 8.5  1.5 8.7  1.4#
Systolic blood pressure (mmHg) 132  18 138  21* 131  17 151  21#
Ever smoking (%) 44.1 55.2* 44.2 53.7#
Total cholesterol (mmol/l) 4.9  0.9 5.2  1.1* 4.9  0.9 5.3  1.0#
Diabetic nephropathy (%) NA NA 15.7 63.3#
Values are expressed as number, means  SD, or percentage. *P  0.05 vs. nonprogressors. #P  0.05 vs. no event. NA, not applicable.
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(P  0.001), and 30 measurements: 1.11 versus 0.87 (P 
0.001). This indicates greater variation with increasing
number of measurements but with conserved differences
in SD between progressors and nonprogressors. There
was no correlation between follow-up time and SD of
serial A1C (Pearson r  0.006, P  0.789).
Kaplan-Meier survival curves with quartiles of SD of
A1C revealed a more clear association between the entire
distribution of variability for progression in renal status
(Fig. 1A) than for CVD events (Fig. 1B), for which only the
highest quartile of SD diverged. In Fig. 2A and B, survival
curves are given for patients with mean and SD of serial
A1C above and below the population medians. For pro-
gression in renal status (Fig. 2A), the highest incidence
was observed when both mean and SD were above the
medians and conversely the lowest incidence when both
were below the medians. Interestingly, patients above
median for mean and below for SD had similar incidence
for progression in renal status as patients below median
for mean and above for SD, suggesting a distinct and
equally important effect of both absolute value and vari-
ability of A1C in the risk of progression in renal disease.
For CVD events, however, a similar ﬁnding was not
observed (Fig. 2B) as all corresponding lines were super-
imposed, probably because of the fact that mean serial
A1C did not differ between patients with and without a
CVD event and all lines contain a prerequisite regarding
the mean serial A1C.
Clinical and lifestyle factors. To depict which baseline
patient characteristics were associated with the variability
TABLE 2
Intrapersonal mean, SD, and coefﬁcient of variation of serially measured A1C values are given compared with progression vs.
nonprogression of renal status or a CVD event (coronary event, stroke, peripheral vascular event) during follow-up
Nonprogressors Progressors P
Mean SD CV Mean SD CV Mean SD CV
Renal status (n  1,893/214) 8.5 0.76 8.9 9.2 1.01 11.0 0.001 0.001 0.001
Normo to Micro (n  1,283/98) 8.3 0.74 8.9 9.2 0.94 10.1 0.001 0.001 0.016
Micro to Macro (n  271/45) 8.8 0.77 8.7 9.6 1.08 11.2 0.001 0.001 0.001
Macro to ESRD (n  231/71) 9.0 0.84 9.2 8.8 1.07 12.0 0.261 0.005 0.001
CVD event (n  1,687/158) 8.5 0.79 9.1 8.6 0.87 10.0 0.423 0.023 0.027
Numbers of patients are given as nonprogressors/progressors. CV is given as percentage. P values are given for nonprogressors vs.
progressors within a given group. CV, coefﬁcient of variation; Normo, normal UAER; Micro, microalbuminuria; Macro, macroalbuminuria.
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FIG. 1. A: Kaplan-Meier survival curves for any progression in renal
status (deﬁned as any increase in albuminuria level or progression to
ESRD) by quartiles of SD of serially measured A1C values. B: Kaplan-
Meier survival curves for a CVD event (coronary event, stroke, peripheral
vascular event) by quartiles of SD of serially measured A1C values.
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FIG. 2. A: Kaplan-Meier survival curves for any progression in renal
status (deﬁned as any increase in albuminuria level or progression to
ESRD) according to mean and SD of serial A1C above and below the
population median. B: Kaplan-Meier survival curves for a CVD event
(coronary event, stroke, peripheral vascular event) according to mean
and SD of serial A1C above and below the population median.
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serial A1C. We found that a higher variability was associ-
ated with younger age, lower age at onset of diabetes,
shorter duration of diabetes, lower insulin sensitivity,
dyslipidemia, higher baseline A1C, both current and ever
smoking, lower socioeconomic class, and lower leisure-
time physical activity (Table 3). For the physical activity,
we included in a separate analysis only patients with
normal UAER, which did not change the results (Table 3).
In patients with normal UAER, the associations for insulin
dose (P  0.001), current smoking (P  0.001), and social
class (P  0.001) with quartiles of SD were similar as for
all patients, suggesting that as for physical activity, the
associations were not solely because of collinearity with
diabetes complications. Finally, because there was a clear
association between age and A1C variability, we also
adjusted the P values for age (Table 3); however, the
abovementioned associations did not change except for
age at onset and duration of diabetes, which were no
longer associated with A1C variability.
Multivariate models. Because of several potential con-
founding factors for the association between the variabil-
ity of serial A1C and the progression of renal disease and
CVD events, we used Cox regression as a multivariate
analysis. As covariates, we used duration of diabetes, sex,
systolic blood pressure, total cholesterol, ever smoking,
intrapersonal mean of serial A1C measurements, and
number (ln-transformed) of A1C measurements. For inci-
dent CVD events, we additionally adjusted for the pres-
ence of diabetic nephropathy and CVD events at baseline.
As shown in Table 4, SD of serial A1C measurements
predicted progression in renal status even independently
of mean serial A1C. Moreover, SD was also an indepen-
dent predictor of CVD events, whereas mean serial A1C
was not.
DISCUSSION
In this study, we show that the variability of A1C predicts
the development and progression of incipient and overt
renal disease in patients with type 1 diabetes. These data
support a recent analysis from the DCCT intervention
where A1C variability predicted the development of dia-
betic nephropathy and retinopathy (5). We add to that
study by showing the same ﬁnding for nephropathy in an
observational cohort and further covering the entire spec-
trum of renal disease (from microalbuminuria to ESRD) in
diabetes. However, the most interesting novel ﬁnding was
that the A1C variability also predicted CVD events even
though the mean A1C during follow-up was similar in
patients with and without a CVD event. This association
was independent of nephropathy status at baseline, indi-
cating that the association was not entirely driven by renal
disease, which is a strong CVD risk factor in patients with
type 1 diabetes (10). We further show that a variable A1C
proﬁle is associated with a cluster of baseline factors such
as lower insulin sensitivity, dyslipidemia, lower socioeco-
nomic status, physical inactivity, and smoking.
In the present longitudinal analysis, the baseline A1C
level was a predictor of incident microalbuminuria and
overt diabetic nephropathy. This is in line with the large
body of evidence showing that lower A1C translates into
reduced risk of diabetic nephropathy and retinopathy in
patients with type 1 diabetes. Before the landmark study
DCCT (1), this was also indicated by the Steno Study (11),
the Oslo Study (12), and the Stockholm Diabetes Interven-
tion Study (13).
Regarding glycemic control and CVD the picture is,
however, less clear. In type 2 diabetes, the apparent lack of
beneﬁt of improved glycemia on CVD outcomes at least in
advanced diabetes has recently been debated (14). In type
TABLE 3
Baseline patient characteristics according to quartiles of A1C variability deﬁned as intrapersonal SD of serial A1C measurements
during follow-up
1st 2nd 3rd 4th P value
P value
adjusted
for age
Patients (n) 529 541 512 525 — —
Sex (% male) 52.8 55.0 51.4 53.7 0.69 0.94
Age (years) 38.1  11.6 37.8  11.7 36.5  11.7 33.2  11.4 0.001 —
Age at onset of diabetes (years) 15.5  8.5 15.0  8.2 14.2  8.5 13.2  8.6 0.001 0.13
Duration of diabetes (years) 22.6  12.3 22.9  11.6 22.4  11.5 20.0  11.8 0.001 0.13
BMI (kg/m
2) 25.0  3.2 25.0  3.1 25.2  3.7 24.9  3.8 0.44 0.47
Waist-to-hip ratio, male 0.90  0.07 0.91  0.08 0.91  0.07 0.90  0.08 0.23 0.22
Waist-to-hip ratio, female 0.82  0.06 0.80  0.06 0.81  0.06 0.82  0.07 0.002 0.001
A1C (%) 7.9  1.2 8.3  1.2 8.6  1.3 9.2  1.9 0.001 0.001
Systolic blood pressure (mmHg) 133  17 133  17 134  19 132  19 0.72 0.10
Diastolic blood pressure (mmHg) 79  97 9  10 80  10 80  10 0.73 0.54
Total cholesterol (mmol/l) 4.9  0.9 4.9  0.9 4.9  0.9 5.0  1.0 0.025 0.001
HDL cholesterol (mmol/l) 1.30  0.37 1.31  0.37 1.32  0.38 1.26  0.36 0.043 0.19
LDL cholesterol (mmol/l) 3.06  0.83 3.02  0.81 3.06  0.82 3.12  0.93 0.25 0.005
Triglycerides (mmol/l) 0.97 (0.73–1.33) 1.02 (0.76–1.43) 1.01 (0.76–1.45) 1.13 (0.85–1.68) 0.001 0.001
Insulin dose (IU/kg) 0.69  0.26 0.71  0.23 0.72  0.24 0.78  0.28 0.001 0.004
eGDR (mg  kg
1  min
1) 6.6 (4.7–8.9) 6.5 (4.4–8.6) 6.3 (4.3–8.4) 6.0 (3.8–8.2) 0.001 0.001
Ever smoker (%) 37.1 44.1 47.3 52.8 0.001 0.001
Current smoker (%) 17.5 21.8 24.2 33.1 0.001 0.001
Blue-collar worker (%) 60.7 63.5 67.9 76.2 0.001 0.001
Sedentary (%), n  775* 19.5 19.1 24.3 28.9 0.087 0.009
Sedentary (%), n  534† 16.0 14.4 23.7 27.7 0.026 0.004
Values are expressed as means  SD, percent, or median (interquartile range). *Patients with available data on physical activity. †Only
patients with normal UAER included. Sedentary, leisure-time physical activity 10 MET*h/week.
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epidemiological studies (17–20), as well as meta-analyses
(21,22), for an independent relationship between A1C and
development of CVD or CVD mortality. In the extended
DCCT follow-up (EDIC), there was a delayed beneﬁt of
intensive treatment on incident CVD (2). There is further a
report that the change in two A1C values (baseline minus
follow-up) predicts incident coronary artery disease in
type 1 diabetes, even though the baseline A1C was not in
itself predictive (23). In the present study, baseline A1C
was slightly higher (0.2% unit) in patients that suffered a
CVD event during follow-up, but the mean serial A1C
during follow-up did not differ between patients with and
without a CVD event during follow-up. Thus, the role of
the level of A1C for CVD is somewhat unclear also in our
study but certainly seems less important than is the case
for diabetic nephropathy.
In addition to the actual level of A1C, it has been
postulated that variation in the glycemic proﬁle also could
contribute to risk of diabetes complications because glu-
cose peaks seem to cause detrimental in vitro cellular
effects (24–27). Furthermore, glycemic excursions mea-
sured by continuous glucose measurement (CGMS) corre-
late with oxidative stress in patients with type 2 diabetes
(3) but not type 1 diabetes (28). Oxidative stress has been
considered fundamental in the pathogenesis of diabetes
complications (29). Furthermore, experimentally induced
oscillating blood glucose may also impair endothelial
function, thus possibly linking glucose ﬂuctuations also to
CVD (30).
For epidemiological studies, the CGMS is often imprac-
tical and other measures of glycemic variability have
therefore been used. In type 2 diabetes, there are some
reports that variability of fasting plasma glucose predicts
retinopathy (31) as well as cardiovascular and total mor-
tality (32). In these studies, however, the patients had
widely differing antihyperglycemic treatment modalities
ranging from diet to insulin injections, which might have
affected the variability. In type 1 diabetes, the variability of
repeated measurements of blood glucose values has been
investigated in the publicly available DCCT dataset by
comparing the quarterly one-day measured pre- and
postprandial (breakfast, lunch, and supper) and bedtime
glucose values (4). The study by Kilpatrick et al. found no
evidence of an effect of variation in blood glucose on the
risk of diabetic nephropathy or retinopathy. Recently
Kilpatrick et al. (5), however, reported that the variability
of A1C in the DCCT independently predicted the incidence
of diabetic nephropathy and retinopathy even after correc-
tion for the absolute level of A1C. Because the DCCT was
an intervention study, the investigators excluded A1C
measurements from the ﬁrst 6 months of the study to
decrease the risk of artiﬁcial variation in A1C because of a
new insulin treatment regimen. The risk of bias by the
intervention itself, however, is still possible, even though
the main ﬁnding was seen in the conventionally treated
nonintervened patient group, which supports an effect
independent of the intervention. Our present study was
performed as a longitudinal, observational study without
intervention, and the results regarding the development of
nephropathy are very similar to the DCCT data (5).
It is likely that the A1C variability reﬂects other pro-
cesses compared with the short-term glycemic variability
observed by CGMS monitoring and multiple blood glucose
measurements. This may explain the difference in the
predictive value of the variability in blood glucose (4) and
the A1C (5) for nephropathy and retinopathy in the DCCT
cohort. The relationship between short-term and long-
term glycemic variability needs to be further clariﬁed. In
our study, the ﬁnding that A1C variability, but not mean
serial A1C, was associated with CVD events might indicate
that patients more severely affected by diabetes and its
complications have a more variable A1C proﬁle than
patients with less complicated disease. Nevertheless, the
association was still evident when controlling for the
presence of diabetic nephropathy and CVD events at
baseline (Table 4). For renal complications, those patients
with a normal UAER at baseline but who progressed to
microalbuminuria had higher A1C variability than those
who remained with normal UAER, suggesting that A1C
variability might not just be secondary to the presence of
more severe diabetes complications.
The mechanisms behind the association between A1C
variability and the risk of diabetes complications are at
this stage merely speculative and cannot be determined in
this observational study. However, several baseline factors
indicative of a disadvantageous lifestyle and a low socio-
economic class were associated with a more variable A1C,
which might indicate a suboptimal management of diabe-
tes. A1C variability was also associated with insulin re-
sistance, which in itself has been implicated in the
pathogenesis of diabetes complications (33). It is also
possible that the intrapersonal variation in A1C is second-
ary to variation in insulin sensitivity, which in turn may be
TABLE 4
Cox regression models for progression in renal status (deﬁned as any increase in albuminuria level or progression to ESRD) and a
CVD event (coronary event, stroke, peripheral vascular event) during a median follow-up of 5.7 years
Progression in renal status CVD event
HR (95% CI) P HR (95% CI) P
Duration of diabetes (years) 1.01 (0.99–1.02) 0.356 1.08 (1.06–1.10) 0.001
Male sex 1.74 (1.30–2.33) 0.001 1.17 (0.81–1.70) 0.399
Systolic blood pressure (mmHg) 1.01 (1.00–1.02) 0.032 1.02 (1.01–1.03) 0.001
Total cholesterol (mmol/l) 1.19 (1.04–1.36) 0.014 1.11 (0.92–1.34) 0.267
Ever smoking 1.22 (0.92–1.63) 0.162 1.00 (0.70–1.43) 0.985
Diabetic nephropathy NA NA 1.78 (1.20–2.64) 0.004
CVD event NA NA 3.11 (2.10–4.59) 0.001
Number of serial A1C measurements 1.09 (0.90–1.31) 0.397 0.88 (0.71–1.09) 0.245
Intrapersonal mean of serial A1C (%) 1.34 (1.20–1.51) 0.001 1.01 (0.87–1.18) 0.892
Intrapersonal SD of serial A1C 1.92 (1.49–2.47) 0.001 1.98 (1.39–2.82) 0.001
Diabetic nephropathy: macroalbuminuria and/or ESRD. Serial A1C represents all available A1C measurements from baseline to follow-up, for
which intrapersonal mean and SD were calculated. All other variables are from baseline. NA, not applicable.
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decrease insulin sensitivity. In fact, we recently showed
that serum lipopolysaccharide activity, a marker of
gram-negative bacterial infections, is associated with
progression of diabetic nephropathy (34). It is further
possible that ﬂuctuating long-term glycemic control
causes homeostatic imbalance, for example, through
intracellular sorbitol accumulation. It was suggested
that the “normoglycemic re-entry phenomenon” (35)
might tie A1C variability and risk of retinopathy (5). This
phenomenon refers to an initial, but not sustained, wors-
ening of retinopathy when lowering A1C in patients al-
ready affected by retinopathy. Similarly, in the kidneys,
variable homeostatic circumstances may be detrimental. A
further potential mechanism is induction of growth fac-
tors, for instance IGF-1 and vascular endothelial growth
factor, by a changing glycemic environment (36,37), which
may contribute to development of diabetes complications.
Regarding CVD, A1C variability may cause vascular
stress by a changing glycemic environment. An impor-
tant remark at this stage, however, is that the available
data on A1C variability and risk of diabetes complica-
tions cannot conﬁrm a direct causal relationship be-
cause the association might be because of collinearity
with other causal factors.
The strengths of this study are the large number of
well-characterized patients and the prospective study de-
sign. There are, however, also limitations to this study. The
serial A1C values were collected from available laboratory
records as a part of the patient’s routine clinical follow-up.
Thus, there were no prespeciﬁed intervals between A1C
measurements, and the number of measurements per
individual patient varied, which was, however, statistically
adjusted for. Another potential limitation is the use of A1C
measured at the local study centers, not in a central
laboratory. However, this should not affect the intraper-
sonal variability of A1C because the measurements were
performed at the same center.
In conclusion, we show in an observational setting that
a larger variability of A1C predicts not only incident
microalbuminuria and progression of established renal
disease but also CVD events in patients with type 1
diabetes.
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